SOMERSET, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced the appointment of Larry Steenvoorden as the new chief financial officer (CFO). With a distinguished career and extensive financial and strategic expertise, Steenvoorden brings valuable experience from his previous roles.
Before joining CareCloud, he served as the executive vice president and CFO at Chembio Diagnostics, where he implemented strategic initiatives and improved profitability. Steenvoorden has also held CFO positions in healthcare, life science, and med-tech companies, providing him with a deep understanding of the unique challenges in the healthcare technology space.
Prior to his industry roles, Steenvoorden held key positions at Siemens AG, including global controller and vice president of business planning and controlling for Siemens Healthcare Diagnostics. He is a certified public accountant with a Bachelor of Science degree in accounting from the University of Delaware and a Master of Business Administration degree from Rider University.
As CareCloud's new CFO, Steenvoorden will play a vital role in the company's financial strategy and growth initiatives. His expertise and track record make him an invaluable addition to the executive team, and his appointment comes at a time when CareCloud is expanding its presence in the healthcare technology market.
"We are thrilled to welcome Larry to CareCloud as our new CFO," said Bill Korn, CareCloud’s former CFO who assumed the role of chief strategy officer in May 2023. "His exceptional financial expertise and industry knowledge will strengthen our financial position and support our mission to revolutionize the healthcare technology landscape. With Larry's guidance, we'll continue driving innovation and delivering unparalleled value to our customers."
"Larry's diverse skill set and dedication to breaking barriers will propel our team to unprecedented success," added Hadi Chaudhry, chief executive officer and president of CareCloud. "With his fresh ideas and profound expertise, we are poised to achieve extraordinary accomplishments, transforming possibilities into realities."
To learn more about how CareCloud is redefining the next generation of technology-enabled revenue cycle solutions, visit carecloud.com.
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.
Follow CareCloud on LinkedIn, Twitter and Facebook.
Company Contact:
Bill Korn
Chief Strategy Officer
CareCloud
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Asher Dewhurst
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries:
Alexis Feinberg
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.25 |
Daily Change: | -0.01 -0.79 |
Daily Volume: | 645,400 |
Market Cap: | US$20.320M |
April 07, 2025 April 02, 2025 March 26, 2025 March 13, 2025 January 28, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load